Table 4.

Summary of antitumor activity

Treatment groupNo. of patientsPatients available by RECIST% of all patients
Single pathway inhibition16011270
PI3K pathway inhibitors1248770
MAPK pathway inhibitors362570
Dual pathways inhibition766585
Best response compared with baselineSingle agent (N = 112)Combination (N = 65)P
Tumor growth (% of patients)85 (76)48 (74)0.86
No change (% of patients)5 (4)0 (0)
Tumor shrinkage (% of patients)22 (20)17 (26)
RECIST
 PR1 (0.9)5 (7.7)0.03
 SD58 (51.8)38 (58.5)0.44
 PD53 (47.3)22 (33.8)0.09
Tumor control rate, % (PR + SD)52.764.60.16
 95% CI by best radiographic response43.5–61.752.5–75.2
SD
 ≥6 mo, %6.310.80.39
 95% CI2.9–12.65.0–20.9
AETB, %19.99.50.02
 95% CI15.0–24.82.5–14.2
 METB, %18.08.0

Abbreviations: AETB, PD, progressive disease; PR, partial response; SD, stable disease.